Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. - Wikidata - wikimedia - TriplyDB

Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers.

Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers.

http://www.wikidata.org/entity/Q40587140

about

Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.Insights into CYP2B6-mediated drug-drug interactions Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.Retinoid X receptor-alpha-dependent transactivation by a naturally occurring structural variant of human constitutive androstane receptor (NR1I3).Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation.Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR.Sucralose, a synthetic organochlorine sweetener: overview of biological issues Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins.Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters.The environmental estrogen, nonylphenol, activates the constitutive androstane receptor.Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR).The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity.Roles of nitric oxide in inflammatory downregulation of human cytochromes P450.Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations.Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine.A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids.Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.Nuclear receptors and nonalcoholic fatty liver disease.HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics.Establishment of In Silico Prediction Models for CYP3A4 and CYP2B6 Induction in Human Hepatocytes by Multiple Regression Analysis Using Azole Compounds.In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies.Applicability of second-generation upcyte® human hepatocytes for use in CYP inhibition and induction studies.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.

P2860

Q24609011-D59038C6-051F-4B51-B03C-6A592AB81484 Q25255438-19B6665B-D9CD-4BE7-BA7C-D11D3A0557C6 Q28078857-FF8F956A-0606-4609-8D2D-8DEDADD4FAD6 Q28478275-05C33A4A-FD9A-4066-A819-8E34C8BA21F3 Q33388541-723B5E7A-4A77-4E7D-A1EB-F0E7B58BEBBA Q33781766-4C9921C7-F215-4199-9739-023A01FC30BE Q33881813-3C33EF39-75AD-4523-9BC9-E6EF0A6AD3C5 Q34149359-08EF6AF6-0114-4C72-B460-A26A93D6AF43 Q34349336-1FC9D493-AF85-4EE5-B9ED-5A80005F1634 Q34657381-2D9B1FDD-86B8-491F-861D-4F83FF2FF3DC Q34737523-121DABEE-5AA6-435E-A6E0-F2D1F6E012B7 Q34824471-11EC52BC-C829-4A1C-9D5B-C39D1E5E9322 Q34826590-81A9AF31-2881-48B6-A49D-27B3F9A219D2 Q35828228-C53BAB60-17BB-4D4D-9425-CF378319A6DC Q35919726-5BB6DEE2-4D49-4ABC-8FBF-D6F69586F30D Q36017105-3973A331-B55A-4846-993C-A3645A449486 Q36473477-57F9676B-07C5-4A92-BE6A-C958E2DB3D02 Q36529490-E7B6404F-60D6-438C-A0AF-73FCFA47DEA5 Q36551142-96D97551-0BFB-443F-84C0-F74B88FD392E Q36593723-0A4FCDF6-3EE1-43EC-832E-6A8A173ED597 Q36593838-CB056EBA-1AE2-4904-B32C-46D47A76D0A4 Q36641884-C46FD697-2136-4A2D-9C77-2ADDCD70FCAD Q36646507-EEC991A9-B11A-4FAF-8394-C57C03071CED Q36657589-4177EF34-6BC1-4802-B3A4-428A959A1659 Q36985079-F1835D4D-F0A3-45A0-B646-A8DE7283F9FE Q37036925-0034293E-02E8-4188-89DD-96E3B51965FD Q37153012-6199FBB9-95D1-41B5-9C84-4FFC087B9579 Q37186259-40EC9085-2846-491B-97DD-4AC229BEEAE3 Q37204170-F30C86E7-5813-4532-85FD-4439B15E2151 Q37262792-C60ED37E-2BF6-4737-9815-9CF9539EE5E0 Q37756178-5E26C1E5-6178-47B6-B413-9DAAEA770A18 Q38634986-26BC5FDF-AC37-4968-8115-10B5D78EBA01 Q38768048-2CAB32CF-9A7D-4859-9028-428623398D1D Q38945994-99DE4531-9692-40F6-A534-6D184FD4E75A Q39747519-E2D8D212-AA46-4C79-B46B-0584FFBDCC75 Q39773047-0925E118-42D3-47A4-B13A-EFBC8BBCC5EC Q39920320-530C2563-7ECE-4C9F-BCBB-7FD06F7E0C01 Q40376125-2364026C-83D8-4C40-B62D-63DE5D115BFC Q40694902-9D182735-51D1-4463-8D87-32C440A0DC63 Q41153557-EC81C7B4-3D9A-405A-8AEF-AC8BD2D119EA

P2860

Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers.

http://www.wikidata.org/entity/Q40587140

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers.

@en

type

label

Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers.

@en

prefLabel

Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers.

@en

P1433

Q40587140-3D123EB4-03C1-4F04-B8E1-A44D3D8AB96B

P1476

Q40587140-88BA8369-302C-4CC7-B716-EC36B082ADAD

P2093

Q40587140-09453266-4C58-40E6-A91A-FD82BA05F62E

Q40587140-19054EC5-4869-4F3F-97AB-809BF67932A3

Q40587140-6B43AF16-558A-45EC-B935-D99991D2B3DB

Q40587140-6C26C417-62F5-41AC-87EC-260F9AFC53C2

Q40587140-A39BBB12-8F2D-4B5E-BCA4-BE73B545CC87

Q40587140-C8387E29-8E12-4782-B8A4-AF2913874155

Q40587140-DF60EA43-77BC-41CA-B6FD-CDECCBF950BC

Q40587140-E9DD2211-1B85-40F4-863A-80DE28E46CD1

P304

Q40587140-DC828ED9-6CDF-4B89-A1F1-C3DF5594246F

P31

Q40587140-62464766-403B-45A1-9505-471262E325FD

P356

Q40587140-D3DDA94C-77F5-4AE9-8274-E0C4D211C467

P433

Q40587140-9EE86D80-650E-45A0-B61E-B07383D898F4

P478

Q40587140-AA77D54C-42F0-4C5B-9DF7-48F31ED3C99B

P50

Q40587140-84303771-0DE3-49ED-A491-B92977EDE3DE

P577

Q40587140-AD86563B-6B0B-464C-AEA1-1193AEBE71AB

P698

Q40587140-7FF65593-0A35-4BA4-9230-FF7604FEE63A

P356

P1433

Drug Metabolism and Disposition

P1476

Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers.

@en

P2093

Bingfang Yan

http://www.w3.org/2001/XMLSchema#string

Celeste Lindley

http://www.w3.org/2001/XMLSchema#string

Darryl Gilbert

http://www.w3.org/2001/XMLSchema#string

Geraldine A Hamilton

http://www.w3.org/2001/XMLSchema#string

Hongbing Wang

http://www.w3.org/2001/XMLSchema#string

Masahiko Negishi

http://www.w3.org/2001/XMLSchema#string

Stephanie R Faucette

http://www.w3.org/2001/XMLSchema#string

Summer L Jolley

http://www.w3.org/2001/XMLSchema#string

P304

348-358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/DMD.32.3.348

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Edward L. LeCluyse

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14977870

http://www.w3.org/2001/XMLSchema#string